Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
update
/
details

Comprehensive National Policy for Rare Diseases (NPRD) 2021: Categorized Treatment, Financial Aid, and Specialized Care Across India

NextEdge Admin

10 Aug 2024

3 min 22 sec

The National Policy for Rare Diseases (NPRD) 2021 launched by the Ministry of Health & Family Welfare, India, aims to address the needs of patients with rare diseases by categorizing these conditions into three groups based on the nature of their treatment requirements.

Key Features of NPRD 2021:

1. Categorization of Rare Diseases:
- Group 1: Disorders amenable to one-time curative treatment (e.g., certain Lysosomal Storage Disorders, immune deficiency disorders, and conditions treatable with hematopoietic stem cell or organ transplantation).
- Group 2: Diseases requiring long-term or lifelong treatment with relatively lower costs (e.g., Phenylketonuria, Tyrosinemia, Cystic Fibrosis).
- Group 3: Diseases with definitive treatment available but requiring optimal patient selection, involving high costs and lifelong therapy (e.g., Gaucher Disease, Pompe Disease, Spinal Muscular Atrophy).

2. Centres of Excellence (CoEs):
- Twelve premier government tertiary hospitals have been designated as CoEs for the diagnosis, prevention, and treatment of rare diseases. These centers provide patients with access to specialized care and financial assistance.

3. Financial Assistance:
- Patients can receive up to ₹50 lakhs for treatment at the CoEs.
- The Ministry has obtained exemptions from GST and Basic Customs Duty on drugs imported for rare diseases.

4. National Consortium for Research:
- The Department of Health Research has established the National Consortium for Research and Development on Therapeutics for Rare Diseases (NCRDTRD) to streamline research activities related to rare diseases.

5. Current Reach:
- As of now, 1,118 patients have benefited from the policy.

Centers of Excellence (CoEs) Include:
- AIIMS, New Delhi
- Maulana Azad Medical College, New Delhi
- Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow
- PGIMER, Chandigarh
- Nizam’s Institute of Medical Sciences, Hyderabad
- King Edward Medical Hospital, Mumbai
- Institute of Post-Graduate Medical Education and Research, Kolkata
- Indira Gandhi Hospital, Bengaluru
- ICH & HC, Chennai
- AIIMS, Jodhpur
- Government Medical College, Thiruvananthapuram
- AIIMS, Bhopal

The policy aims to reduce the burden on patients with rare diseases by providing both financial support and access to specialized care.